Ocular toxicities associated with antibody drug conjugates and immunotherapy in Oncology: Clinical Presentation, Pathogenesis, and management Strategies
Expert Opin Drug Saf. 2023 Aug 23. doi: 10.1080/14740338.2023.2251380. Online ahead of print.ABSTRACTINTRODUCTION: development of molecularly targeted anticancer therapies and immunotherapy continues to revolutionize treatment of cancer. FDA accelerated approvals of novel targeted therapies allowed for introduction of these agents into the clinic at a rapid rate. On-and off-target ocular toxicities are prevalent treatment-related adverse events of newer therapies including antibody drug conjugates (ADCs) and immunotherapy. Ocular toxicities associated with ADCs and immunotherapy have heterogeneous presentations and pathoge...
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Farah Raheem Nada Alsuhebany Erin Hickey Zacholski Nikola Paulic Anna Sandler Nathan Uk Donald C Moore Source Type: research
Pregnancy-related Adverse Events associated with statins: A Real-World Pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)
CONCLUSIONS: Statins did not increase the risk of pregnancy-related AEs, including abortion, abortion spontaneous or stillbirth/fetal death. However, we did find significant disproportionality signals for preterm birth and low birth weight associated with pravastatin, and lovastatin was related to a higher proportion of fetal complications. The results in this study may provide evidence on the safety of statins during pregnancy, which need to be verified in further investigations.PMID:37612600 | DOI:10.1080/14740338.2023.2251888 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Tingxi Wu Yanfeng Shi Bin Zhu Dandan Li Zhe Li Zhigang Zhao Yang Zhang Source Type: research
Cardiovascular toxicities following the use of tyrosine kinase inhibitors in Hepatocellular Cancer Patients: A Retrospective, Pharmacovigilance Study
CONCLUSION: Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients.PMID:37608525 | DOI:10.1080/14740338.2023.2251398 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Xin Lai Qing Wan Shou-Feng Jiao Xiao-Chun Sun Jin-Fang Hu Hong-Wei Peng Source Type: research
Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
CONCLUSIONS: Our study identified new AEs that have not been reported, which provides a new guidance to deepen the comprehension of the safety of Ubrogepant.PMID:37608560 | DOI:10.1080/14740338.2023.2251390 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Bing Cao Shanshan Gu Zhisen Shen Yuna Zhang Yiming Shen Hang Chen Source Type: research
Ocular adverse Events of cenegermin Used in neurotrophic Keratopathy: An Analysis of the FDA adverse event reporting system Database
CONCLUSION: This study revealed new cenegermin-related ocular AE signals. Clinical practice requires close monitoring to early identify and manage adverse reactions that may cause occurrence of serious irreversible consequences.PMID:37608598 | DOI:10.1080/14740338.2023.2251389 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Yunfei Li Haiyun Yang Yuan Gao Weimin He Source Type: research
